Associations between elevated depressive symptoms and substance use, prescription opioid misuse, overdose history, pain, and general health among community pharmacy patients prescribed opioids

References

• Substance Abuse and Mental Health Services Administration. (2020). Key substance use and mental health indicators in the United States: Results from the 2019 National Survey on Drug Use and Health (HHS Publication No. PEP20-07-01-001, NSDUH Series H-55). Rockville, MD: Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration. https://www.samhsa.gov/data/.
   Google Scholar
• Boudreau D, Von Korff M, Rutter CM, et al. Trends in long-term opioid therapy for chronic non-cancer pain. Pharmacoepidemiol Drug Saf. 2009;18(12):1166–1175.
   PubMed Web of Science ®Google Scholar
• Von Korff M, Saunders K, Thomas Ray G, et al. De facto long-term opioid therapy for noncancer pain. Clin J Pain. 2008;24(6):521–527.
   PubMed Web of Science ®Google Scholar
• Arteta J, Cobos B, Hu Y, Jordan K, Howard K. Evaluation of how depression and anxiety mediate the relationship between pain catastrophizing and prescription opioid misuse in a chronic pain n population. Pain Med. 2016;17(2):295–303.
   PubMed Web of Science ®Google Scholar
• Banta-Green CJ, Merrill JO, Doyle SR, Boudreau DM, Calsyn DA. Opioid use behaviors, mental health and pain-development of a typology of chronic pain patients. Drug Alcohol Depend. 2009;104(1–2):34–42.
   PubMed Web of Science ®Google Scholar
• CDC. Vital signs: overdoses of prescription opioid pain relievers and other drugs among women — United States, 1999–2010. Morbid Mortal Week Rep. 2013;62(26):537–542.
   PubMedGoogle Scholar
• Gadermann AM, Alonso J, Vilagut G, Zaslavsky AM, Kessler RC. Comorbidity and disease burden in the National Comorbidity Survey Replication (NCS-R). Depress Anxiety. 2012;29(9):797–806.
   PubMed Web of Science ®Google Scholar
• Brooks JM, Petersen C, Kelly SM, Reid MC. Likelihood of depressive symptoms in US older adults by prescribed opioid potency: National Health and Nutrition Examination Survey 2005–2013. Int J Geriatr Psychiat. 2019;34(10):1481–1489.
   PubMed Web of Science ®Google Scholar
• Feingold D, Brill S, Goor-Aryeh I, Delayahu Y, Lev-Ran S. The association between severity of depression and prescription opioid misuse among chronic pain patients with and without anxiety: a cross-sectional study. J Affect Disord. 2018;235:293–302.
   PubMed Web of Science ®Google Scholar
• Gilam G, Sturgeon JA, You DS, Wasan AD, Darnall BD, Mackey SC. Negative affect-related factors have the strongest association with prescription opioid misuse in a cross-sectional cohort of patients with chronic pain. Pain Med. 2020;21(2):e127–e138.
   PubMedGoogle Scholar
• Grattan A, Sullivan MD, Saunders KW, Campbell CI, Von Korff MR. Depression and prescription opioid misuse among chronic opioid therapy recipients with no history of substance abuse. Ann Fam Med. 2012;10(4):304–311.
   PubMed Web of Science ®Google Scholar
• Sullivan MD. Depression effects on long-term prescription opioid use, abuse, and addiction. Clin J Pain. 2018;34(9):878–884.
   PubMed Web of Science ®Google Scholar
• Grigsby TJ, Howard JT. Prescription opioid misuse and comorbid substance use: Past 30-day prevalence, correlates and co-occurring behavioral indicators in the 2016 National Survey on Drug Use and Health. Am J Addict. 2019;28(2):111–118.
   PubMed Web of Science ®Google Scholar
• Johnson EM, Lanier WA, Merrill RM, et al. Unintentional prescription opioid-related overdose deaths: description of decedents by next of kin or best contact, Utah, 2008–2009. J Gen Intern Med. 2013;28(4):522–529.
   PubMedGoogle Scholar
• Bair MJ, Robinson RL, Katon W, Kroenke K. Depression and pain comorbidity: a literature review. Arch Intern Med. 2003;163(20):2433–2445.
   PubMed Web of Science ®Google Scholar
• Cochran G, Brown JL, Yu Z, et al. Validation and threshold identification of a prescription drug monitoring program clinical opioid risk metric with the WHO alcohol, smoking, and substance involvement screening test. Drug Alcohol Depend. 2021;228:109067.
   PubMedGoogle Scholar
• Hamilton CM, Strader LC, Pratt JG, et al. The PhenX Toolkit: get the most from your measures. Am J Epidemiol. 2011;174(3):253–260.
   PubMed Web of Science ®Google Scholar
• Kroenke K, Spitzer RL, Williams JBW. The Patient Health Questionnaire-2: validity of a two-item depression screener. Med Care. 2003;41(11):1284–1292.
   PubMed Web of Science ®Google Scholar
• WHO ASSIST Working Group. The Alcohol, Smoking and Substance Involvement Screening Test (ASSIST): development, reliability and feasibility. Addiction. 2002;97(9):1183–1194.
   PubMed Web of Science ®Google Scholar
• Knisely JS, Wunsch MJ, Cropsey KL, Campbell ED. Prescription Opioid Misuse Index: a brief questionnaire to assess misuse. J Subst Abuse Treat. 2008;35(4):380–386.
   PubMed Web of Science ®Google Scholar
• Fernandez AC, Bush C, Bonar EE, Blow FC, Walton MA, Bohnert ASB. Alcohol and drug overdose and the influence of pain conditions in an addiction treatment sample. J Addict Med. 2019;13(1):61–68.
   PubMed Web of Science ®Google Scholar
• Ware J, Jr., Kosinski M, Keller SD. A 12-Item Short-Form Health Survey: construction of scales and preliminary tests of reliability and validity. Med Care. 1996;34(3):220–233.
   PubMed Web of Science ®Google Scholar
• Keller S, Bann CM, Dodd SL, Schein J, Mendoza TR, Cleeland CS. Validity of the brief pain inventory for use in documenting the outcomes of patients with noncancer pain. Clin J Pain. 2004;20(5):309–318.
   PubMed Web of Science ®Google Scholar
• Palos GR, Mendoza TR, Mobley GM, Cantor SB, Cleeland CS. Asking the community about cutpoints used to describe mild, moderate, and severe pain. J Pain. 2006;7(1):49–56.
   PubMed Web of Science ®Google Scholar
• Stata Statistical Software: Release 14. StataCorp LP; 2015. College Station, TX: StataCorp LP.
   Google Scholar
• Cochran G, Bacci JL, Ylioja T, et al. Prescription opioid use: patient characteristics and misuse in community pharmacy. J Am Pharm Assoc. 2016;56(3):248–256.e6.
   Google Scholar
• Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med. 2001;16(9):606–613.
   PubMed Web of Science ®Google Scholar
• Scherrer JF, Salas J, Sullivan MD, et al. The influence of prescription opioid use duration and dose on development of treatment resistant depression. Prev Med. 2016;91:110–116.
   PubMed Web of Science ®Google Scholar
• Sullivan MD, Edlund MJ, Zhang L, Unützer J, Wells KB. Association between mental health disorders, problem drug use, and regular prescription opioid use. Arch Intern Med. 2006;166(19):2087–2093.
   PubMedGoogle Scholar
• Villarroel MA, Terlizzi EP. Symptoms of depression among adults: United States, 2019. NCHS data brief. 2020;379:1–8. https://www.cdc.gov/nchs/products/databriefs/db379.htm.
   Google Scholar
• Quello SB, Brady KT, Sonne SC. Mood disorders and substance use disorder: a complex comorbidity. Sci Pract Perspect. 2005;3(1):13–21.
   PubMedGoogle Scholar
• Fishbain DA, Cutler R, Rosomoff HL, Rosomoff RS. Chronic pain-associated depression: antecedent or consequence of chronic pain? A review. Clin J Pain. 1997;13(2):116–137.
   PubMed Web of Science ®Google Scholar
• Elliott TE, Renier CM, Palcher JA. Chronic pain, depression, and quality of life: correlations and predictive value of the SF-36. Pain Med. 2003;4(4):331–339.
   PubMed Web of Science ®Google Scholar
• Brown JL, Vanable PA. The effects of assessment mode and privacy level on self-reports of risky sexual behaviors and substance use among young women. J Appl Social Psychol. 2009;39(11):2756–2778.
   Web of Science ®Google Scholar